FEATURED EDITORIAL
Startup founders of Resilientia Tx discuss protecting cancer patients from radiation side effects, organ-on-a-chip discovery, Nucleate Boston, and early startup challenges.
- 2026 Nucleate Boston Activator Cohort Interview: Carlos Ezio — Criocore
- 2026 Nucleate Boston Activator Cohort Interview: Anna Kazatskaya — Fervid Therapeutics, previously Antozero
- Strategic Synthesis Of ASGCT And ASCO 2026
- 2026 Nucleate Boston Activator Cohort Interview: Michael Cronce — Omni Therapeutics
- A New De Novo Protein Design Platform For GPCR Drug Discovery
- Advancing Spatial Multiomics for Discovery: From Promise to Practice
- Discovery Dialogues: Winston Haynes, VP, Computational Sciences and Engineering, LabGenius Tx
FEATURED APPLICATION CONTENT
-
See how a biotechnology company advanced an engineered protein therapeutic while navigating development, regulatory, and scalability challenges.
-
Integrated accelerated stability workflows reduce manual data handling while improving confidence in shelf‑life predictions. Help your teams move faster with fewer experimental demands.
-
Confident identification of known and unknown compounds starts with smarter LC/MS and GC/MS workflows. Learn how structure elucidation, verification, and centralized data curation work together.
-
Gain insight into how localized modeling of ionizable centers, supported by curated experimental data, delivers reliable predictions that strengthen physicochemical decision-making.
-
Property-driven optimization helps medicinal chemists focus synthetic effort where it matters most. See how integrating ADME and physicochemical predictions can surface better-balanced lead candidates.
-
Digital integration of physicochemical property prediction transforms how chemists evaluate compounds, enabling faster analysis, stronger structure, and more informed decisions across libraries.
-
Automated structure verification integrated into open-access NMR workflows cuts review time dramatically while maintaining confidence in results. See how smart parameter optimization improves efficiency.
-
High-throughput chemistry delivers speed and efficiency, but only with the right digital backbone. See how integrated automation and analytics help chemists extract more value from every plate.
-
AI‑enabled DMTA cycles connect design, experimentation, and analysis through structured data and automation, reducing manual handoffs while accelerating discovery, development, and CMC decision‑making.
-
Managing analytical data across instruments doesn’t have to slow decision-making. Learn how a vendor-neutral, multi-technique approach helps chemists access, process, and report results efficiently.
-
Automated screening paired with in silico modeling can cut method development time while improving robustness. See how combining experimentation and simulation enables faster decision‑making.
-
Standardized analytical data is key to improving data quality, reuse, and AI readiness. Explore the challenges of fragmented formats and gain practical guidance on building future-proof foundations.
- 2026 Nucleate Boston Activator Cohort Interview: Ryan Posey & Anusha Manglik — Resilientia Therapeutics
- 2026 Nucleate Boston Activator Cohort Interview: Dr. Chathuraka Jayasuriya — EnkaBio
- 2026 Nucleate Boston Activator Cohort Interview: Chris Clifford — Mimic Therapeutics
- 2026 Nucleate Boston Activator Cohort Interview: Carlos Ezio — Criocore
- 2026 Nucleate Boston Activator Cohort Interview: Anna Kazatskaya — Fervid Therapeutics, previously Antozero
DRUG DISCOVERY CONTENT COLLECTIONS
Drug discovery is moving beyond traditional hit identification toward data-driven strategies that extract deeper insight from large-scale screening datasets. Advances in DNA-encoded library (DEL) screening, computational tools, and machine learning are helping teams make more informed decisions in early-stage drug development. Access this brand-new Drug Discovery Online content collection for an under-the-hood look at modern approaches to turning large discovery datasets into actionable insight.
FEATURED NEWS HEADLINES
- Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical And AI Companies To Accelerate AI-enabled Drug Discovery
- XtalPi Announces Strategic Partnership With A Leading Biopharma To Develop Oral Small Molecule Therapeutics For A GPCR Target
- US FDA Grants Orphan Drug And Rare Pediatric Disease Designations To GEn1E Lifesciences' Dual Signal Modulator For The Treatment Of Duchenne Muscular Dystrophy
- Perpetual Medicines And Third Rock Ventures Deliver A Development Candidate In Under 18 Months Via Computational Physics And AI-Driven Platform
- OpenFold Consortium Adds Eleven New Members As Momentum Builds For Open AI Infrastructure In Biology And Drug Discovery
- Owkin To Build AI Agents As Part Of A Multi-Year K Pro Collaboration With Sanofi
- DaltonTx Launches Its Drug Discovery Platform, Dalton, And Announces Sygnature Discovery Collaboration
- Chai Discovery Announces License Agreement With Pfizer To Accelerate Drug Discovery With AI
- Terremoto Biosciences Granted FDA Fast Track Designation For TER-2013, An AKT1-Selective Small Molecule Inhibitor For Breast Cancer
- Ingenix Raises €13M From Sofinnova Partners-Led Syndicate To Scale Modality Fusion, A Novel Architecture For Drug Development
ARCHIVED NEWSLETTER
- 06.09.26 -- Validation And Trust Are Biggests Barriers To Organ On Chip Adoption
- 06.06.26 -- Drug Discovery Online Best Of May
- 05.19.26 -- From Urine-Derived To Recombinant Precision: KLK1 Reimagined For Preeclampsia
- 05.02.26 -- Drug Discovery Online Best Of April
- 04.29.26 -- Master pipetting, PCR, and NGS for cell and gene workflows.
